Chronic obstructive pulmonary disease: a growing but neglected global epidemic

Peter J Barnes, Peter J Barnes

Abstract

Peter Barnes argues that COPD is a major and increasing global health epidemic that has received insufficient attention from the health-care profession, governments, and the pharmaceutical industry.

Conflict of interest statement

Competing Interests: The author has declared that no competing interests exist.

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2006. Available: . Accessed 11 April 2007.
    1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J. 2006;27:397–412.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. 2006. PLoS Med 3: e442. doi: .
    1. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet. 2005;366:1875–1881.
    1. Xu F, Yin X, Zhang M, Shen H, Lu L, et al. Prevalence of physician-diagnosed COPD and its association with smoking among urban and rural residents in regional mainland China. Chest. 2005;128:2818–2823.
    1. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:188–207.
    1. British Thoracic Society. The burden of lung disease. 2006. Available: . Accessed 11 April 2007.
    1. Barnes PJ, Kleinert S. COPD—A neglected disease. Lancet. 2004;364:564–565.
    1. Smith KR. National burden of disease in India from indoor air pollution. Proc Natl Acad Sci U S A. 2000;97:13286–13293.
    1. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Eng J Med. 2004;350:1005–1012.
    1. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: A 25 year follow up study of the general population. Thorax. 2006;61:935–939.
    1. Tashkin DP, Kanner R, Bailey W, Buist S, Anderson P, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo controlled, randomised trial. Lancet. 2001;357:1571–1575.
    1. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161:381–390.
    1. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;26:835–845.
    1. Barnes PJ. Reduced histone deacetylase in COPD: Clinical implications. Chest. 2006;129:151–155.
    1. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet. 2004;364:985–996.
    1. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J. 2003;22:672–688.
    1. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, et al. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med. 2005;142:233–239.
    1. UK Clinical Research Collaboration. UK health research analysis. 2006. Available: . Accessed 11 April 2007.
    1. The PLoS Medicine Editors. Are we publishing “the right stuff”? 2006. PLoS Med 3: e512. doi: .

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj